Corcept Therapeutics Inc (CORT) stock analysis
Close on Nov 11, 2026Market cap $8.06BP/E 177.5Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed11 of 30 checks passed
Corcept Therapeutics passes 11 of the 30 checks behind our score; 5 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 3/6
- Past performance
- 2/6
- Financial health
- 6/6
- Dividend
- 0/6
What stands out
No debt
Corcept Therapeutics has no borrowings on its latest balance sheet.
Revenue growing 10%+ a year
Revenue grew 23.7% a year over the last three fiscal years.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
Margin of safety under 20%
The price is 352% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $74.53 is above our fair value estimate of $16.49.
Return on equity under 15%
Return on equity was 8.2% over the last twelve months and averaged 21.6% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 1.9%, below the 10% that usually covers the cost of capital.
Valuation0/6
P/E above its 5-year median
Corcept Therapeutics's P/E of 177.5 is above its own 5-year median of 32.8.
P/E above the industry
Corcept Therapeutics's P/E of 177.5 is above the Drugs median of 25.1.
EV/EBITDA above its 5-year median
Corcept Therapeutics's EV/EBITDA of 958.5 is above its 5-year median of 25.2.
P/B above the industry
Corcept Therapeutics's price-to-book of 11.42 is above the Drugs median of 2.29.
Trading above fair value
The share price of $74.53 is above our fair value estimate of $16.49.
Margin of safety under 20%
The price is 352% above fair value, so there is no margin of safety.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 23.7% a year over the last three fiscal years.
EPS growing under 10% a year
Diluted EPS grew -2.0% a year over the last three fiscal years.
Earnings growth not accelerating
Net income grew -58.7% over the last twelve months, against a 5-year average of -1.2% a year.
Growing faster than the industry
Revenue grew 16.0% over the last twelve months; the Drugs median is 8.0%.
Guidance raised
Corcept Therapeutics raised its 2026 revenue guidance outlook on Jul 29, 2026.
Gross margin slipping
Gross margin was 98.3% over the last twelve months, against 98.4% a year earlier.
Past performance2/6
Return on equity under 15%
Return on equity was 8.2% over the last twelve months and averaged 21.6% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was 1.9%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Corcept Therapeutics's return on equity of 8.2% is above the Drugs median of -58.9%.
Earnings shrank over 5 years
Net income shrank 1.2% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was 6.6% over the last twelve months, against a 5-year average of 22.4%.
Net margin above the industry
Corcept Therapeutics's net margin of 6.6% is above the Drugs median of -53.0%.
Financial health6/6
No debt
Corcept Therapeutics has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 2.86 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 28.80; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Corcept Therapeutics has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$16.49
The share price is 352% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 29.0× | 32.8× | 25.1× | $12.17 | 62% |
| EV/EBITDAleft out, too far from the others | 21.2× | 25.2× | 17.1× | $4.43 | – |
| P/B | 4.7× | 7.2× | 2.3× | $30.95 | 15% |
| Earnings power | 7.8% cost of equity | – | – | $18.36 | 23% |
| Fair value | $16.49 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 32.8
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $101.06M
- Value traded per 1% price move
- $45.61M
Downside
High risk
- Typical loss in a bad month
- 57.4%
- Volatility (annualized)
- 83%
- Sharpe ratio, 1 year
- -0.07
- Beta to the S&P 500 (5Y)
- 0.59
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +12.8% | +23.7% | +16.6% | +31.2% | |
| Gross profit | +12.7% | +23.6% | +16.5% | +31.4% | |
| Operating income | -67.3% | -26.5% | -19.0% | – | |
| Net income | -29.4% | -0.6% | -1.2% | – | |
| EPS, diluted | -33.3% | -2.0% | -0.7% | – | |
| Free cash flow | -27.7% | +5.7% | -1.2% | +46.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 27.2% | 23.7% | 15.0% | |
| Return on assets | 13.5% | 21.5% | 11.9% | |
| Current ratio | 2.40 | 10.07 | 2.92 | |
| Debt to equity | 0.35 | – | – | |
| Net debt to EBITDA | -3.59× | – | – | |
| Inventory turnover | 1.0× | 1.1× | 1.0× | |
| Capex to revenue | 0.2% | 0.3% | 0.0% | |
| Diluted shares | 116M | 124M | 120M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Corcept Therapeutics generated $755.19M from operations and spent $191.98M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 13.1% | 0.91× | 1.26× | 15.0% |
| FY2024 | 20.9% | 0.92× | 1.23× | 23.8% |
| FY2023 | 22.0% | 0.80× | 1.19× | 21.0% |
| FY2022 | 25.2% | 0.80× | 1.15× | 23.1% |
| FY2021 | 30.7% | 0.74× | 1.11× | 25.0% |
| FY2020 | 30.0% | 0.72× | 1.10× | 23.7% |
| FY2019 | 30.7% | 0.85× | 1.12× | 29.1% |
| FY2018 | 30.0% | 0.94× | 1.14× | 32.3% |
| FY2017 | 81.1% | 1.10× | 1.25× | 111.1% |
| FY2016 | 10.0% | 1.35× | 2.02× | 27.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$99.65M
- Cash generatingOperating cash flow above zero$142.00M
- Return on assets improvedROA up on the prior year22.7% → 11.9%
- Earnings backed by cashOperating cash flow above net income$142.00M vs $99.65M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.35 → 2.92
- No dilutionShare count did not rise113M → 120M
- Gross margin improvedGross margin up on the prior year98.39% → 98.30%
- More efficientAsset turnover rose1.09 → 0.91
See a number that looks wrong?